FEELM
FEELM, the flagship atomization technology platform belonging to SMOORE - the world’s largest vape manufacturer, has won Best Innovation in the Vaping Industry and Sustainable Vaping Award at the UKVIA Industry Forum.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221121005487/en/
FEELM won the UKVIA Best Innovation Award. (Photo: Business Wire)
UKVIA is one of the world's most influential trade associations for the vaping sector. It is also one of the most accredited industrial association in Europe. This is the first time they held an award competition ever since their establishment in 2016. The competition is consisted of three sessions: online application, audiences review, and experts scoring. FEELM Max won the victory after rounds of assessments of more than 300 audiences and 10 experts.
The Best Innovation in the Vaping Industry
The Best Innovation in the Vaping Industry recognized the significant contribution FEELM has made to vaping innovation, particularly its world's first ceramic coil disposable pod solution FEELM Max.
FEELM Max has made a number of breakthrough innovations, including more puffs with the same e-liquid volume versus other coil technologies. Despite heating the same e-liquid volume as other conventional devices, puff numbers increase by more than 25%. FEELM Max achieves a flavour consistency of over 95% as well as a smoother vapour – and there is no dry burning – thanks to Constant Output Control and our Patented Flavour-Lock Technologies. Not only is FEELM Max enhancing the vaping experience, but it is also outperforming other disposables on harm reduction by almost 50%.
To stand still on the path of innovation, FEELM has established China’s first PMTA-standard testing lab besides the now-existing 14 labs globally, to empower our clients facing with the stringent regulations on the industry. This is to prove our determination to drive innovation with technology, and keep providing products with enhanced quality to consumers.
The Sustainable Vaping Award
The Sustainable Vaping Award was given in recognition of FEELM excelling in three key areas: creating sustainable advanced technologies and products; using responsible marketing; and embracing a greener future.
FEELM is credited with building the world's first environmentally friendly disposable electronic atomization device in 2019. In 2022, the world's first ceramic coil disposable pod "FEELM Max" was created and the "FEELM GREEN" series was launched based on it. This series is FEELM Max's main environmental protection solutions, its latest "product is packaging" series has been presented at the major European electronic atomization exhibition, aroused the industry's high attention. In addition, FEELM also created an environmentally friendly zero nicotine e-atomization device this year.
It was also acknowledged that its brand website and social media platforms go to great lengths to restrict those who are under the legal age of vaping to prevent them from accessing any information about electronic atomization products; and that FEELM conducts regular satisfaction surveys on behalf of clients so data can be used to improve customer experience.
FEELM has announced its launching of the Carbon Disclosure Project (CDP), committing to achieve carbon neutrality by 2050, and its automated factory has adopted an energy management system with the purpose of decreasing carbon emissions whilst increasing energy consumption efficiency
The Award is also recognition of FEELM’s cut in carbon emissions of over 500 tons in the last six months, and its aim to lower greenhouse gas emissions and achieve Scope 1 and Scope 2 carbon neutrality by 2050. The company intends to achieve this by improving energy efficiency and increasing the use of renewable energy sources to 30% of total consumption by 2030 and has accordingly introduced a professional carbon neutral energy screening team and internal resources to monitor carbon consumption improvement. It has also partnered with a third-party cleaning company to collect non-hazardous waste for recycling, which in 2020 helped clients reduce single-use plastics by 100 tons – equivalent to 4 million plastic bottles, while in 2021 it reduced its water consumption by 9.4% year-on-year.
Echo liu, FEELM Europe Division Director said:
“We are delighted to have won both awards and honoured by the recognition the UKVIA have given us.”
“A number of leading vaping brands are driven by FEELM Technology, and our vaping devices loaded with FEELM atomizer are now being exported to over 50 countries and regions.”
“FEELM can only realize its corporate vision – “atomization makes life better” – by being sustainable and creating value for society. Every day we move a step closer to this goal by creating sustainable advanced technologies and products, using responsible marketing, and embracing a greener future.”
For more information or journalist queries, please contact us via feelm@smooretech.com.
About FEELM:
As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.
About SMOORE:
SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components for HNB products on an ODM basis, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base.
According to Frost & Sullivan, SMOORE is the world’s largest vaping device manufacturer in terms of revenue, accounting for 22.8% of the total global market share in 2021. Its global market share is bigger than the sum of those listed from No.2 to No.5.
About the UKVIA:
The UK Vaping Industry Association (UKVIA) is the #1 trade association for the vaping sector supporting, developing, and promoting the £1bn vaping industry, the UK’s largest growing consumer goods sector. Its vision is a world where the evidence-based, life-changing public health benefits of vaping products are fully understood so that their positive impact can be maximised.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221121005487/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MSCI Announces Baer Pettit to Retire as President17.11.2025 13:00:00 CET | Press release
Additional senior leadership changes will drive growth in new client segments and products MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced that C.D. Baer Pettit, President and Chief Operating Officer (COO), and a member of the Board of Directors, has informed the company that he will retire next year after more than 25 years in senior leadership roles. Mr. Pettit will continue to serve as President and a Director until March 1, 2026, and will remain as an advisor to the company for a period of time to ensure a smooth transition. Mr. Pettit joined MSCI in 2000 and has served in numerous senior leadership roles, including heading Client Coverage, Marketing and Index. He was appointed COO in 2015 and President in 2017, overseeing all products and operations, and he joined the Board of Directors in 2023. “Baer has been my longtime business partner, and he has played a pivotal role in shaping MSCI’s st
AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth17.11.2025 13:00:00 CET | Press release
Dr Lee is a seasoned biopharmaceutical executive with a proven track record of leading cross-functional teams to successfully develop and commercialize innovative therapies in oncology AdvanCell Pty Ltd (“AdvanCell”), a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Philina Lee, PhD as Chief Executive Officer and member of the Board of Directors. Dr Lee will head AdvanCell’s US expansion, accelerating clinical, manufacturing, and partnership activities to advance lead clinical candidate 212Pb-ADVC001 and the company’s innovative radiopharmaceutical portfolio. She will assume her role from January 1, 2026, and will be based at the company’s new US headquarters near Boston/Cambridge, MA. “Philina brings a rare combination of global commercial leadership, deep radiopharmaceutical expertise, and an outstanding record of building high growth organizations and high-performance teams,” said Andrew Kay, C
Connections, Local Flavors, and Luxurious Experiences Top the 2026 Bacardi Cocktail Trends Report17.11.2025 13:00:00 CET | Press release
This year’s findings highlight a move towards more meaningful occasions, micro-indulgence, and storytelling cocktail experiences The five defining trends set to reshape cocktail culture and the spirits industry in 2026 are highlighted in the seventh annual Bacardi Cocktail Trends Report. The Report released by Bacardi Limited, the largest privately held international spirits company, in partnership with The Future Laboratory (TFL), draws on data from Bacardi-led and third-party research, consumer surveys, bartender interviews and TFL’s trend forecasting to uncover the forces shaping cocktail experiences, flavor innovation, and drinking culture in the year ahead. The Report also reveals the cocktails which are set to be the most popular in 2026 and trends for younger Legal Drinking Age (LDA) consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117678098/en/ The 7th annual Bacardi Cocktail Trends Report unveils what an
Arada to Acquire Majority Stake in £2.5bn Thameside West Development, Unlocking One of London’s Largest and Most Connected New Waterfront Neighbourhoods17.11.2025 12:58:00 CET | Press release
Arada, the UAE’s fastest-growing master developer, announces that it has agreed the acquisition of an 80% stake in Thameside West, a landmark waterfront mixed-use development located at the western end of London’s Royal Docks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117374964/en/ HH Sheikh Sultan bin Ahmed Al Qasimi, Chairman of Arada (centre) with members of the Arada and Keystone executive teams (Photo: AETOSWire) Master-planned by Foster + Partners, the vibrant new urban destination will deliver at least 5,000 homes, with half of the site dedicated to green space and a kilometre of active waterfront. Boasting unrivalled transport links, the integration of air, road, rail, river and tunnel links makes this one of the most connected sites in London. Spread over a 47-acre area – twice the size of the Hudson Yards mixed-use development in New York - Thameside West represents one of Europe’s largest and most strategi
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 12:00:00 CET | Press release
ZIIHERAplus TEVIMBRA and chemotherapy demonstrated clinically meaningful and statistically significant improvements in PFS and OS versus trastuzumab and chemotherapyZIIHERA plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first interim analysisFirst Phase 3 trial in 15 years to demonstrate a clinical benefit in this patient population with a novel HER2-targeted therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
